Tislelizumab
Gliosarcoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
39 Active assets in the Gliosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan RTOG Foundation, Inc. | Phase 3 | BB |
(+)-VINCRISTINE RTOG Foundation, Inc. | Phase 3 | BB |
Cyclophosphamide Mayo Clinic | Phase 2 | BB |
Ipilimumab University College, London | Phase 2/3 | BB |
Rindopepimut Celldex Therapeutics | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Tislelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →